The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | FOLL12: MRD monitoring in patients with FL
Stefano Luminari, MD, University of Modena and Reggio Emilia, Modena, Italy, discusses minimal residual disease (MRD) monitoring in the Phase III FOLL12 trial (EudraCT: 2012-003170-60), which compared rituximab maintenance against a positron emission tomography (PET)/MRD response-based post-induction approach in patients with advanced follicular lymphoma (FL). MRD was measured with peripheral blood and bone marrow samples. Early relapse in patients was accurately predicted using MRD and whilst bone marrow was more sensitive in detecting MRD, Prof. Luminari highlights the prognostic value of using peripheral blood samples. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
